Sirio Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Peiqing Li
Chief executive officer
CN¥1.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 9.2% |
| Management average tenure | no data |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
When Should You Buy Sirio Pharma Co., Ltd. (SZSE:300791)?
Dec 13
Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?
Oct 14The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More
Sep 30Is Sirio Pharma (SZSE:300791) Using Too Much Debt?
Sep 23Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares
Aug 01Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around
Jun 30Is Sirio Pharma (SZSE:300791) A Risky Investment?
Jun 12An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued
Apr 24Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly
Mar 06CEO
Peiqing Li (59 yo)
no data
Tenure
CN¥1,842,800
Compensation
Mr. Peiqing Li has been Chairman of the Board and General Manager at Sirio Pharma Company Limited since April 23, 2015 and serves as its Non-Independent Director.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | no data | CN¥1.84m | 9.21% CN¥ 614.0m | |
| Deputy GM & Director | 9.7yrs | CN¥1.62m | 5.61% CN¥ 374.1m | |
| Director | 9.7yrs | CN¥120.00k | 3.26% CN¥ 217.4m | |
| Director | 9.7yrs | CN¥1.77m | 2.65% CN¥ 176.9m | |
| Independent Director | 3.4yrs | CN¥120.00k | no data | |
| Independent Director | 3.4yrs | CN¥120.00k | no data | |
| Independent Director | 3.4yrs | CN¥120.00k | no data | |
| Non-Employee Supervisor | 3.4yrs | no data | no data | |
| Supervisor | 2.2yrs | no data | no data |
3.4yrs
Average Tenure
54yo
Average Age
Experienced Board: 300791's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sirio Pharma Co., Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Huang | Chasing Securities |
| Wenbo Chen | China International Capital Corporation Limited |
| Wendan Wang | China International Capital Corporation Limited |